AstraZeneca lowers vaccine efficacy in trial amid data concerns in U.S.

Economy Society

AstraZeneca Plc said Wednesday that its coronavirus vaccine was 76 percent effective at preventing symptomatic illness in a clinical trial, slightly lowering the rate after facing questions in the United States over its data. An interim analysis of the trial, which took place in the United States, Peru and Chile, showed Monday that the vaccine efficacy was 79 percent. But the U.S. National Institute of Allergy and Infectious Diseases said a day later that the British company may have included "outdated" information from the trial when reporting the results, possibly providing an "incomplete vi...

Kyodo News

Kyodo News Society